Analysts think VKTX stock price could increase by 179%
Nov 09, 2025, 12:25 PM
3.33%
What does VKTX do
Viking Therapeutics, based in San Diego, develops therapies for metabolic and endocrine disorders, including VK2809 for NASH, VK0214 for X-ALD, and VK2735 for metabolic issues. The company went public on April 29, 2015, and has 28 employees.
18 analysts think VKTX stock price will increase by 178.82%. The current median analyst target is $102.51 compared to a current stock price of $36.77. The lowest analysts target is $36.36 and the highest analyst target is $131.25.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.